《慢性阻塞性肺疾病全球创议(2024版)》解读:嗜酸性粒细胞和2型炎症  

Interpretation of the Global Initiative for Chronic Obstructive Lung Disease(2024 report):eosinophils and type 2 inflammation

作　　者：廖艺璇 郭岩斐[1] Liao Yiruan;Guo Yanfei(Department of Pulmonary and Critical Care Medicine,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]北京医院呼吸与危重症医学科,国家老年医学中心,中国医学科学院老年医学研究所,北京100730

出　　处：《国际呼吸杂志》2024年第6期637-642,共6页International Journal of Respiration

基　　金：首都卫生发展科研专项(2024-2-4057)。

摘　　要：慢性阻塞性肺疾病(慢阻肺)是一种常见的慢性气道炎症性疾病,具有一定的异质性。部分慢阻肺患者表现为以嗜酸性粒细胞(EOS)增加为特征的2型炎症内型。《慢性阻塞性肺疾病全球创议(2024版)》新增血EOS计数作为慢阻肺初始评估指标之一,提出用血EOS计数来预测吸入性糖皮质激素(ICS)在预防未来急性加重方面的作用,并指导ICS应用。本文就EOS与2型炎症在慢阻肺患者临床治疗和预后方面的进展进行解读,以期为慢阻肺的精准个体化治疗提供参考。Chronic obstructive pulmonary disease(COPD)is a common chronic airway inflammatory disease with certain heterogeneity.Some patients with COPD present with type 2 inflammation characterized by an increase in eosinophils(EOS).Interpretation of the Global Initiative for Chronic Obstructive Lung Disease 2024 report added a blood EOS count as one of the initial evaluation measures for COPD,proposing to use blood EOS counts to predict the effect of inhaled corticosteroids(ICS)in preventing future exacerbation and to guide ICS use.This article reviewed the research progress of EOS and type 2 inflammation in the clinical prognosis and treatment of patients with COPD,in order to provide reference for the precise and personalized treatment of COPD.

关 键 词：肺疾病 慢性阻塞性 肺嗜酸粒细胞增多 2型炎症 糖皮质激素类 分子靶向治疗 

分 类 号：R563.9[医药卫生—呼吸系统]